SCHEMBL489728

SCHEMBL489728

C[SiH2]O.Cn1c(=O)c2[nH]c(CC(=O)O)nc2n(C)c1=O

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.63
CYP2C19 P33261 2/20 0.63
CYP1A2 P05177 1/20 0.63
POLB P06746 2/20 0.58
HSD17B10 Q99714 2/20 0.57
CYP3A4 P08684 1/20 0.57
CASP1 P29466 1/20 0.57
CASP7 P55210 1/20 0.57
KDM4E B2RXH2 1/20 0.53
PABPC1 P11940 1/20 0.52
TSHR P16473 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
RXFP1 Q9HBX9 1/20 0.50
ADORA2A P29274 2/20 0.47
ADORA2B P29275 2/20 0.47
ADORA1 P30542 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL340194 0.94 ALDH1A1 (0.69) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL1705540 0.92 ALDH1A1 (0.66) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
Acetic Acid SCHEMBL3776954 0.92 ALDH1A1 (0.66) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL18338822 0.86 ALDH1A1 (0.50) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL5718021 0.82 POLB (0.62) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL6153958 0.82 ALDH1A1 (0.51) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL4311418 0.81 POLB (0.61) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL3389758 0.81 ALDH1A1 (0.82) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL925084 0.78 ALDH1A1 (0.92) ALDH1A1CYP2C19CYP1A2POLBHSD17B10
SCHEMBL3368846 0.78 POLB (0.69) ALDH1A1CYP2C19CYP1A2POLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10179103-B1 Anti-cellulite cream JAN MARINI SKIN RESEARCH (US) 2019-01-15 US claimed
EP-4103144-B1 COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS SYMRISE AG (DE) 2026-05-27 EP disclosed
US-12629323-B2 Cosmetic kit and its use as a make-up product Oxygen Innovation SRL (IT) 2026-05-19 US disclosed
WO-2026087745-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-30 WO disclosed
EP-4732825-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-29 EP disclosed
EP-4110277-B1 COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS SYMRISE AG (DE) 2026-04-22 EP disclosed
US-20260096978-A1 A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS SYMRISE AG (DE) 2026-04-09 US disclosed
EP-4025675-B1 A PERFUME OIL MIXTURE SYMRISE AG (DE) 2026-03-18 EP disclosed
EP-4706780-A2 COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS Symrise AG (DE) 2026-03-11 EP disclosed
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2026-02-19 US disclosed
US-20050004274-A1 Gel compositions HEALY LIN LU (US) 2005-01-06 US disclosed
EP-0971686-B1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN BEIERSDORF AG (DE) 2004-11-03 EP disclosed
WO-2004037221-A1 METHOD FOR COSMETIC BODY TREATMENT TO ENHANCE THE SILHOUETTE AND TO DEVELOP THE FEMALE BUST, AND DOUBLE-ACTING COSMETIC COMPOSITION THEREFOR INSTITUT JEANNE PIAUBERT (FR) 2004-05-06 WO disclosed
EP-1256336-A2 Two-phase gel composition Penreco (US) 2002-11-13 EP disclosed
US-20020055562-A1 Gel compositions WILMINGTON TRUST, NATIONAL ASSOCIATION 2002-05-09 US disclosed
US-20020025303-A1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN BOOTS COMPANY, THE PLC (GB) 2002-02-28 US disclosed
EP-1141111-A1 GEL COMPOSITIONS Penreco (US) 2001-10-10 EP disclosed
WO-2000026285-A1 GEL COMPOSITIONS PENRECO (US) 2000-05-11 WO disclosed
EP-0971686-A1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN The Boots Company PLC (GB) 2000-01-19 EP disclosed
WO-1998044904-A1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN THE BOOTS COMPANY PLC (GB) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629323-B2 Cosmetic kit and its use as a make-up product KCNN1, LAGE3, CACNA2D1 ALDH1A1 1686/4885CYP2C19 4614/4885CYP1A2 4840/4885
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL RBP4, LRAT, RARB ALDH1A1 156/4885CYP2C19 4225/4885CYP1A2 3874/4885
US-20260096978-A1 A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS PTGS2, PTGES2, PTGS1 ALDH1A1 705/4885CYP2C19 743/4885CYP1A2 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.